培美曲塞联合替吉奥治疗复发转移性乳腺癌的临床效果

Abstract
Figure/Table
References (16)
Related Citation (9)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo observe and analyze the clinical efficacy and adverse reactions of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer.MethodsFrom August 2015 to August 2016,56 patients with recurrent metastatic breast cancer in our hospital were selected and randomly divided into the control group and the observation group,28 cases in each group.In the observation group,Pemetrexed combined with Tegafur Gimeracil Otera was adopted,every 3 weeks was considered as a treatment cycle.In the control group,only Tegafur Gimeracil Otera was used,every participant should be treated for at least two cycles,and effect and adverse reactions were evaluated between the two groups.ResultsIn the observation group,the survival rate and recurrence rate were 75.00%and 3.57%respectively,which were both superior to those in the control group(35.71%,39.29%),with significant difference(P＜0.05).There was no significant difference between the two groups in mortality(P＞0.05).The incidence of digestive tract reaction in the observation group was 32.14%,the incidence rate of hematologic toxicity was 46.43%,and the incidence of liver function toxicity was 32.14%,which were lower than those in the control group(57.14%,72.43%,25.00%),with significant difference (P＜0.05).There was no significant difference in the incidence of neurotoxicity and liver function toxic reaction between the two groups(P＞0.05).ConclusionCombination of Pemetrexed and Tegafur Gimeracil Otera can obtain a remarkable effect on treating recurrent metastatic breast cancer in a low adverse reactions.It can be tolerated and is worthy of clinical promotion and research.

Key words： Pemetrexed Tegafur Gimeracil Otera Recurrent metastatic breast cancer Clinical observation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Min
	ZHAO Jian-hua

Cite this article:

WANG Min,ZHAO Jian-hua. Clinical effect of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer[J]. 中国当代医药, 2017, 24(29): 53-55.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I29/53

[1]	胡旭明，杨小红.替吉奥治疗晚期转移性乳腺癌的临床疗效观察[J].中国医药导刊，2014，16（11）：1410-1411.
[2]	袁晓荣，孟令茹，于焕欣，等.培美曲塞联合卡培他滨治疗复发转移性乳腺癌临床观察[J].肿瘤基础与临床，2015，28（5）：396-398.
[3]	许崇德.培美曲塞治疗复发转移乳腺癌的疗效观察[J].中国医院药学杂志，2012，32（5）：361-363.
[4]	任章霞，李凡，杨蕙嘉，等.替吉奥联合多西他赛治疗蒽环类药物耐药的复发转移性乳腺癌的临床观察[J].中国药房，2013，24（48）：4571-4573.
[5]	陈良，张道良，张颖，等.培美曲赛联合IL-2治疗恶性胸腔积液的临床研究[J].中华肿瘤防治杂志，2012，19（19）：1503-1506.
[6]	文玲波，杨兰平.长春瑞滨联合替吉奥治疗蒽环类和紫杉类耐药复发转移性乳腺癌的临床观察[J].实用癌症杂志，2013，28（3）：253-255.
[7]	翟军厚.多西他赛联合卡培他滨治疗复发转移性乳腺癌的疗效及对CEA、CA199的影响[J].中国现代医生，2017，55（11）：30-32.
[8]	柏方，陈婷，刘艳，等.培美曲塞脂质体的制备及其对乳腺癌的作用观察[J].上海交通大学学报（医学版），2017，37（2）：190-192.
[9]	杜峰，王苗，尹先哲.多西他赛联合替吉奥治疗复发转移性乳腺癌的临床研究[J].现代医学，2012，40（4）：464-466.
[10]	刘荫华，高国璇.转移性乳腺癌外科手术应用价值及选择[J].中国实用外科杂志，2015，35（7）：718-720.
[11]	丁荣楣，王平，马丽君，等.替吉奥联合放疗对复发转移性乳腺癌的疗效及安全性评价[J].河北医药，2016，38（5）：687-690.
[12]	笪洁，杜瀛瀛，卜丽佳，等.替吉奥单药三线治疗转移性乳腺癌的临床研究[J].中华疾病控制杂志，2015，19（7）：751-753.
[13]	吕民豪，秦丽，李军涛，等.原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J].肿瘤防治研究，2015，93（8）：782-788.
[14]	王芳，郝春芳，贾勇圣，等.205例初治转移性乳腺癌的临床病理特点和生存分析[J].中国肿瘤临床，2014，41（17）：1103-1107.
[15]	刘君，肖扬，郭建雄，等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究，2016，43（1）：72-77.
[16]	谢家印，向大开，王东，等.多西他赛联合替吉奥治疗复发转移性乳腺癌的临床分析[J].第三军医大学学报，2011，33（22）：2414-2416.